Nov 26 (Reuters) – Novavax Inc said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.
The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.
“The initial work will take a few weeks,” a company spokesperson said. Shares of the company closed up nearly 9% on Friday.
Strange. Omicron was first reported to the WHO 72 hours ago. It was officially designated by WHO 24 hours ago. And Novavax is already saying a ‘vaccine’ will be ready in a fortnight – less time than home brew companies advise customers to ferment amber ales and light lagers. Sure. I’ll have that injected into my body. Not.